...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Diabetes therapy >The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type?2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics
【24h】

The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Type?2 Diabetes Patients (TROPHIES): Design and Baseline Characteristics

机译：杜拉格替纳和黎射叶蛋白患者的真实观测治疗健康结果的前瞻性研究？2糖尿病患者（奖杯）：设计和基线特征

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionThe TROPHIES observational study enrolled patients with type?2 diabetes mellitus (T2DM) initiating their first injectable treatment with the glucagon-like peptide?1 receptor agonists (GLP-1?RAs) dulaglutide or liraglutide. This manuscript focuses on the study design, baseline characteristics of the enrolled population, and factors associated with GLP-1?RA choice.MethodsTROPHIES is a prospective, observational, 24-month study conducted in France, Germany, and Italy. Inclusion criteria include adult patients with T2DM, na?ve to injectable antihyperglycemic treatments, initiating dulaglutide or liraglutide per routine clinical practice. The primary outcome is the duration of treatment on dulaglutide or liraglutide without a significant treatment change.ResultsThe analysis included 2181 patients (dulaglutide, 1130; liraglutide, 1051) (cutoff date May?15, 2019). The population was 56% male with mean [standard deviation (SD)] patient characteristics at baseline as follows: age, 59.2 (11.0) years; body mass index (BMI), 33.9 (6.6) kg/m 2 ; T2DM duration, 8.5 (6.9) years; and glycated hemoglobin (HbA1c), 8.2 (1.3)%. Between-cohort demographic and clinical characteristics were balanced. The mean (SD) HbA1c and BMI values for French, German, and Italian patients were, respectively, 8.6 (1.4)%, 8.2 (1.4)%, 8.0 (0.8)%; 33.3 (6.1) kg/m 2 , 36.0 (7.2) kg/m 2 , and 32.6 (5.9) kg/m 2 .ConclusionThis study analysis at baseline provides an opportunity to evaluate between-country differences in baseline HbA1c, weight, macrovascular complications, and factors driving GLP-1?RA selection for patients with T2DM in daily practice.
机译：介绍奖杯观察性研究注册了患有型糖尿病（T2DM）的患者，其首先用胰高血糖素肽（GLP-1 -1-RAS）杜拉蛋白或Liraglutide的第一个可注射治疗。该稿件专注于研究设计，纳入人口的基准特征，以及与GLP-1相关的因素。RA Choice.5.ethodstrophies是在法国，德国和意大利进行的前瞻性，观测的24个月的研究。纳入标准包括成年患者T2DM，Na ve，可注射的抗血糖治疗，每种常规临床实践启动杜拉替偶或丽格葡萄肽。主要结果是在杜拉替偶或丽菌蛋白酶上治疗的持续时间，没有显着治疗的变化。分析包括2181名患者（杜拉格尔蛋白剂，1130; Liraglutide，1051）（截止日期可能会？2019年15,5,2019）。人口为56％的男性，平均[标准偏差（SD）]基线患者特征如下：年龄，59.2（11.0）年;体重指数（BMI），33.9（6.6）kg / m 2; T2DM持续时间，8.5（6.9）岁;和糖化血红蛋白（HBA1c），8.2（1.3）％。 - 群组之间的人口统计学和临床​​特征是平衡的。法语，德语和意大利患者的平均值（SD）HBA1C和BMI值分别为8.6（1.4）％，8.2（1.4）％，8.0（0.8）％; 33.3（6.1）kg / m 2,36.0（7.2）kg / m 2和32.6（5.9）kg / m 2。基准的研究分析提供了评估基线HBA1c，体重，大血管并发症之间的国家差异的机会和驾驶GLP-1的因素为T2DM在日常实践中的患者选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号